Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA advisory panel backs Novavax COVID-19

By Brian Buntz | June 7, 2022

NovavaxNovavax (Nasdaq:NVAX) has won unanimous backing from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) for its NVX-CoV2373 COVID-19 vaccine.

Voting 21 to 0 with one abstention, the VRBPAC recommended that FDA grant emergency use authorization (EUA) to the vaccine for adults 18 and older.

The Novavax would be the fourth vaccine to win authorization in the U.S., following the vaccines from Johnson & Johnson, Moderna, and Pfizer and its partner BioNTech.

The vaccine is likely to win authorization by June, estimated M. Nielsen Hobbs, an analyst for Informa Pharma Intelligence.

While several companies are reading next-generation COVID-19 vaccines, the Novavax vaccine is “not so much a new entrant as a much delayed initial entrant as part of Operation Warp Speed,” Hobbs said.

If it wins authorization, the Novavax vaccine would be the first protein-based COVID-19 vaccine in the U.S.

Earlier this week, FDA released a briefing document noting that it had some concerns related to the Novavax vaccine’s potential to cause myocarditis. In a statement, Novavax downplayed those concerns, pointing to balanced rates of myocarditis between placebo and vaccine recipients in clinical studies.

At present, roughly 30% of Americans remain unvaccinated.

Demand has fallen for the Johnson & Johnson vaccine after federal authorities have recommended constraining its use.

While the NVX-CoV2373 vaccine is protein-based and thus has a similar profile to traditional vaccines for influenza, hepatitis B, shingles and other diseases, it remains unclear how much demand there will be for the new vaccine.

As COVID-19 vaccines and boosters have become available to an incrementally larger swath of the population, the demand for the shots has fallen. “With each new iteration, whether via the third dose or the first inoculations in teens and younger kids, a smaller and smaller percentage of people got jabs,” Hobbs said. “There is a population that was inclined to have gotten their initial shots but didn’t come back for their boosters and didn’t vaccinate their kids.”

After Nasdaq temporarily halted trading of NVAX shares today, the company’s stock price was up 20.57% to $57.48.


Filed Under: Infectious Disease, Uncategorized
Tagged With: Novavax, NVX-CoV2373, Vaccines and Related Biological Products Advisory Committee, VRBPAC
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Amylyx
Amylyx notches first global approval for oral ALS therapy Albrioza
Sage and Biogen
Zuranolone could offer rapid relief from postpartum depression 
Trikafta wins Canadian approval for Trikafta in children with cystic fibrosis
Moderna
Moderna seeks FDA blessing for second COVID-19 vaccine booster

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50